Firebrick Pharma (ASX:FRE) has launched its first international product, Nasodine throat spray, in Singapore, marking a key milestone for the company's global expansion plans.
The 1% povidone-iodine throat spray complements the existing Nasodine nasal spray by targeting sore throats, often the first sign of the common cold, and offers a convenient, travel-friendly alternative to traditional gargles.
Following shipment from Australia in early January 2026, the product is initially being introduced to hospitals and healthcare professionals through the company's exclusive licensing partner, Innorini Life Sciences, before broader retail availability later this year.
Priced at S$19.99, the throat spray is designed with a precise nozzle and low-volume spray for targeted relief without the need to expectorate.
Firebrick plans to expand Nasodine throat spray to Fiji, the USA, and other markets in 2026, alongside additional innovative products.
At the time of reporting, Firebrick Pharma's share price was $0.063.